Velpatasvir

31 interactions 4 explained in plain English
Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Jul 4, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Major

Velpatasvir Abametapir Explained Increased exposure of CYP3A4 substrate Details Velpatasvir Omeprazole Gastrobim Explained Decreased velpatasvir exposure Details Velpatasvir Relugolix Orgovyx Explained Increased relugolix exposure Details Velpatasvir Alpelisib Piqray Increased alpelisib exposure and an increased risk of alpelisib-related adverse effects and toxicity Details Velpatasvir Atogepant Qulipta Increased atogepant exposure Details Velpatasvir Capmatinib Tabrecta Increased P-gp substrate exposure and an increased risk of increased adverse reactions Details Velpatasvir Cyclosporine Injection Atopica Increased cycloSPORINE exposure Details Velpatasvir Cyclosporine Ophthalmic Cequa Increased cycloSPORINE exposure Details Velpatasvir Dabigatran Pradaxa® Increased dabigatran exposure and an increased risk of bleeding Details Velpatasvir Dabigatran Etexilate Increased dabigatran exposure and an increased risk of bleeding Details Velpatasvir Dexamethasone Injection Decadron Reduced velpatasvir plasma concentrations Details Velpatasvir Dexamethasone Ophthalmic Dexacidin® (as a combination product containing Dexamethasone, Neomycin, Polymyxin B) Reduced velpatasvir plasma concentrations Details Velpatasvir Dexlansoprazole Dexilant Decreased velpatasvir exposure Details Velpatasvir Digoxin Cardoxin® Increased digoxin exposure Details Velpatasvir Doxorubicin Adriamycin Increased DOXOrubicin exposure and an increased risk of DOXOrubicin-related adverse reactions Details Velpatasvir Eluxadoline Viberzi Increased eluxadoline exposure Details Velpatasvir Esomeprazole Nexium Decreased velpatasvir exposure Details Velpatasvir Esomeprazole Injection Nexium Decreased velpatasvir exposure Details Velpatasvir Lansoprazole Prevacid Decreased velpatasvir exposure Details Velpatasvir Lefamulin Xenleta Increased lefamulin exposure and an increased risk of lefamulin-related adverse reactions Details Velpatasvir Lenacapavir Injection Sunlenca Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse reactions Details Velpatasvir Lenacapavir Oral Sunlenca Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse reactions Details Velpatasvir Letermovir Injection Prevymis Increased CYP3A substrate exposure Details Velpatasvir Loperamide Diamode Increased loperamide exposure and an increased risk of loperamide-related adverse effects Details Velpatasvir Morphine Injection Astramorph® PF Increased morphine exposure and an increased risk of morphine-related adverse effects (hypotension, respiratory depression, profou... Details Velpatasvir Nafcillin Injection Unipen® Injection Reduced velpatasvir plasma concentrations Details Velpatasvir Nevirapine Viramune Reduced velpatasvir plasma concentrations Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.